Bristol Myers Squibb (BMY): Q1 2026 Earnings Preview and What to Watch
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $10.93 billion, a roughly 2.5% decline year-over-year.
- Consensus adjusted EPS (earnings per share) is forecasted at $1.44-$1.46, reflecting ongoing transition dynamics.
- Growth Portfolio, including key immuno-oncology drugs like Opdivo, is anticipated to show continued momentum offsetting legacy product declines.
- Company reaffirmed 2026 guidance for revenue of $46-$47.5 billion and adjusted EPS of $6.05-$6.35.
- Q4 2025 revenue hit $12.5 billion, up 1% YoY, with Growth Portfolio surging 16% to $7.4 billion.
- Investors watching for updates on pipeline progress and Eliquis demand amid patent challenges.
Earnings Context and Why It Matters
As Bristol Myers Squibb's Q1 2026 earnings, due on April 30, 2026, draw near, this report feels particularly pivotal. The company is in the midst of a strategic shift, with its Growth Portfolio now accounting for nearly 60% of sales. Legacy blockbusters like Revlimid are dealing with post-patent erosion, but newer assets in oncology and immunology are stepping up to offset those declines. Recent quarters demonstrate resilience—Q4 2025 saw Growth Portfolio growth of 16%—yet overall revenue faces ongoing pressures from industry pricing and competition. For investors like myself, this earnings release provides key insights into execution against 2026 guidance and potential pipeline catalysts, which could influence BMY's valuation in a sector that rewards sustainable innovation.
Earnings Expectations
Wall Street's projections point to Q1 revenue of $10.92-$10.94 billion, down about 2.5% from last year, as legacy declines are partially tempered by Growth Portfolio gains. The consensus for adjusted EPS lands at $1.44-$1.46, which could mark a year-over-year drop influenced by margin pressures and R&D investments. I'm particularly focused on metrics like Growth Portfolio performance, Eliquis volumes, and Opdivo market share. BMY has a track record of beating revenue estimates lately, as seen in Q4 2025's $12.5 billion against expectations. Post-earnings stock moves have been mixed, averaging a slight -0.1%, with upside typically tied to strong guidance reaffirmations.
Market Reaction and Investor Sentiment
Sentiment heading into these Q1 results strikes me as cautiously optimistic, supported by the Q4 beats and positive 2026 guidance, even with the anticipated revenue dip. Options pricing suggests a ~4-5% stock move after the report, in line with historical volatility. Shares climbed after the recent Q4 despite legacy softness, indicating the market's emphasis on the growth trajectory. That said, risks loom, such as potential guidance cuts or underwhelming pipeline updates in a competitive oncology environment.
Tools I Use: Tickeron’s AI Screener
One tool I turn to regularly when analyzing stocks like BMY is Tickeron’s AI Screener, an AI-powered platform for discovering stocks and ETFs. It lets me filter thousands of names using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI-driven signals—far more efficiently than manual screening. Whether spotting trade ideas, breakout candidates, or industry comparables, it streamlines my process and highlights opportunities I might otherwise miss. If you're looking to deepen your market scans, it's worth exploring.
Forward Outlook and Key Factors to Monitor
Post-Q1, I'll be watching closely for reaffirmation of the 2026 guidance: revenue of $46-47.5 billion and adjusted EPS of $6.05-$6.35, driven by Growth Portfolio expansion toward over 60% of sales. From what I see, pipeline milestones—like Opdivo combinations and launches such as Cobenfy (KarXT)—will be crucial, especially amid Eliquis pricing pressures and patent cliffs. Cost discipline in R&D and manufacturing could help margins hold up. I also checked BMY's trends using Tickeron’s AI Trend Prediction Engine to gauge momentum.
Broader dynamics, including biosimilar competition and M&A activity, deserve attention too. Key upcoming catalysts involve mid-year data readouts and regulatory decisions that could shape long-term demand.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for BMY shows an upward move is likely
BMY's Aroon Indicator triggered a bullish signal on August 24, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 197 similar instances where the Aroon Indicator showed a similar pattern. In of the 197 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 18, 2026. You may want to consider a long position or call options on BMY as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on August 21, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BMY moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
BMY broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.158) is normal, around the industry mean (19.422). P/E Ratio (14.819) is within average values for comparable stocks, (33.317). Projected Growth (PEG Ratio) (2.378) is also within normal values, averaging (11.305). Dividend Yield (0.037) settles around the average of (0.027) among similar stocks. P/S Ratio (2.795) is also within normal values, averaging (4.270).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor
Advertisement